Form 8-K - Current report:
SEC Accession No. 0001193125-25-018385
Filing Date
2025-01-31
Accepted
2025-01-31 16:05:27
Documents
13
Period of Report
2025-01-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d914351d8k.htm   iXBRL 8-K 24442
  Complete submission text file 0001193125-25-018385.txt   146107

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20250127.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20250127_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20250127_pre.xml EX-101.PRE 11259
15 EXTRACTED XBRL INSTANCE DOCUMENT d914351d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 25578379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)